Drug intelligence / Profile preview

IW-3718

Development stage: Discontinued
Lead developer: Ironwood Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

IW-3718 is a gastric-retentive formulation of colesevelam, a bile acid sequestrant. It was designed to maintain the bile-acid sequestrant in the stomach over an extended period of time where it could intercept bile before it reached the esophagus. The drug was developed for the treatment of refractory gastroesophageal reflux disease (GERD) in patients who continued to experience symptoms such as heartburn and regurgitation despite receiving proton pump inhibitor (PPI) therapy.

Other names: colesevelam

Beyond the preview

Go deeper on IW-3718.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IW-3718.

Explore the full profile